Denmark
· Delayed Price · Currency is DKK Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of DKK 1.93 trillion. The enterprise value is 2.01 trillion.
| Market Cap | 1.93T |
| Enterprise Value | 2.01T |
Important Dates
The next estimated earnings date is Wednesday, August 6, 2025.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | Mar 28, 2025 |
Share Statistics
Novo Nordisk has 4.44 billion shares outstanding. The number of shares has decreased by -0.61% in one year.
| Current Share Class | 3.36B |
| Shares Outstanding | 4.44B |
| Shares Change (YoY) | -0.61% |
| Shares Change (QoQ) | -0.20% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 32.73% |
| Float | 3.18B |
Valuation Ratios
The trailing PE ratio is 18.54 and the forward PE ratio is 16.22. Novo Nordisk's PEG ratio is 1.12.
| PE Ratio | 18.54 |
| Forward PE | 16.22 |
| PS Ratio | 6.37 |
| PB Ratio | 13.95 |
| P/TBV Ratio | 66.26 |
| P/FCF Ratio | 24.42 |
| P/OCF Ratio | 14.72 |
| PEG Ratio | 1.12 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.82, with an EV/FCF ratio of 25.39.
| EV / Earnings | 19.21 |
| EV / Sales | 6.63 |
| EV / EBITDA | 12.82 |
| EV / EBIT | 13.69 |
| EV / FCF | 25.39 |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.86.
| Current Ratio | 0.74 |
| Quick Ratio | 0.54 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | 0.76 |
| Debt / FCF | 1.50 |
| Interest Coverage | 41.95 |
Financial Efficiency
Return on equity (ROE) is 88.12% and return on invested capital (ROIC) is 47.91%.
| Return on Equity (ROE) | 88.12% |
| Return on Assets (ROA) | 23.29% |
| Return on Invested Capital (ROIC) | 47.91% |
| Return on Capital Employed (ROCE) | 58.02% |
| Revenue Per Employee | 3.92M |
| Profits Per Employee | 1.35M |
| Employee Count | 77,349 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.22 |
Taxes
In the past 12 months, Novo Nordisk has paid 27.69 billion in taxes.
| Income Tax | 27.69B |
| Effective Tax Rate | 20.93% |
Stock Price Statistics
The stock price has decreased by -55.96% in the last 52 weeks. The beta is 0.22, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | -55.96% |
| 50-Day Moving Average | 450.05 |
| 200-Day Moving Average | 632.02 |
| Relative Strength Index (RSI) | 37.87 |
| Average Volume (20 Days) | 5,033,345 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novo Nordisk had revenue of DKK 303.14 billion and earned 104.62 billion in profits. Earnings per share was 23.48.
| Revenue | 303.14B |
| Gross Profit | 256.61B |
| Operating Income | 146.82B |
| Pretax Income | 132.31B |
| Net Income | 104.62B |
| EBITDA | 155.29B |
| EBIT | 146.82B |
| Earnings Per Share (EPS) | 23.48 |
Balance Sheet
The company has 41.55 billion in cash and 118.72 billion in debt, giving a net cash position of -77.17 billion or -17.39 per share.
| Cash & Cash Equivalents | 41.55B |
| Total Debt | 118.72B |
| Net Cash | -77.17B |
| Net Cash Per Share | -17.39 |
| Equity (Book Value) | 138.54B |
| Book Value Per Share | 31.21 |
| Working Capital | -61.72B |
Cash Flow
In the last 12 months, operating cash flow was 131.25 billion and capital expenditures -52.11 billion, giving a free cash flow of 79.13 billion.
| Operating Cash Flow | 131.25B |
| Capital Expenditures | -52.11B |
| Free Cash Flow | 79.13B |
| FCF Per Share | 17.83 |
Margins
Gross margin is 84.65%, with operating and profit margins of 48.43% and 34.51%.
| Gross Margin | 84.65% |
| Operating Margin | 48.43% |
| Pretax Margin | 43.65% |
| Profit Margin | 34.51% |
| EBITDA Margin | 51.23% |
| EBIT Margin | 48.43% |
| FCF Margin | 26.10% |
Dividends & Yields
This stock pays an annual dividend of 11.40, which amounts to a dividend yield of 2.52%.
| Dividend Per Share | 11.40 |
| Dividend Yield | 2.52% |
| Dividend Growth (YoY) | 21.28% |
| Years of Dividend Growth | 7 |
| Payout Ratio | 48.56% |
| Buyback Yield | 0.61% |
| Shareholder Yield | 3.12% |
| Earnings Yield | 5.41% |
| FCF Yield | 4.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 13, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Sep 13, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Novo Nordisk has an Altman Z-Score of 7.88 and a Piotroski F-Score of 5.
| Altman Z-Score | 7.88 |
| Piotroski F-Score | 5 |